Literature DB >> 19371237

Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy.

Maja Mockenhaupt1.   

Abstract

The spectrum of severe drug-induced skin reactions includes not only Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) but also generalized bullous fixed drug eruption (GBFDE), acute generalized exanthematous pustulosis (AGEP) and hypersensitivity syndrome (HSS), also called drug reaction with eosinophilia and systemic symptoms (DRESS). These reactions differ in clinical presentation as well as prognosis, causative agents and therapy. Therefore, the appropriate diagnostic measures should be undertaken rapidly, in order to prove the diagnosis. In addition to a thorough clinical examination, a skin biopsy should be taken and specific laboratory investigations should be done if AGEP or HSS/DRESS is suspected. Since these reactions are drug-induced, the causative agent should be rapidly identified and withdrawn. Besides adequate supportive therapy, systemic immunomodulatory treatments may be considered. Despite intensive care management, the prognosis in SJS and TEN is often poor and influenced by the amount of skin detachment as well as the age of the patients and the pre-existing underlying conditions. Severe sequelae may develop in survivors and affect especially mucosal sites. The prognosis of GBFDE is better but recurrent events may lead to more severe involvement. In HSS/DRESS sequelae have been also described as well as long lasting and recurrent courses, whereas AGEP usually heals without problems.

Entities:  

Mesh:

Year:  2009        PMID: 19371237     DOI: 10.1111/j.1610-0387.2008.06878.x

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  26 in total

Review 1.  [Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): a review].

Authors:  S Ständer; D Metze; T Luger; T Schwarz
Journal:  Hautarzt       Date:  2013-08       Impact factor: 0.751

Review 2.  Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes.

Authors:  Manuel Florian Struck; Peter Hilbert; Maja Mockenhaupt; Beate Reichelt; Michael Steen
Journal:  Intensive Care Med       Date:  2009-09-29       Impact factor: 17.440

Review 3.  [Dermatological conditions requiring intensive care].

Authors:  C Marks; R Marks
Journal:  Hautarzt       Date:  2012-09       Impact factor: 0.751

4.  Systematic review of treatments for Stevens-Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality.

Authors:  Jean-Claude Roujeau; Sylvie Bastuji-Garin
Journal:  Ther Adv Drug Saf       Date:  2011-06

Review 5.  In vitro testing for diagnosis of idiosyncratic adverse drug reactions: Implications for pathophysiology.

Authors:  Abdelbaset A Elzagallaai; Michael J Rieder
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

6.  Clinical characteristics and treatment outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Hiroshi Chantaphakul; Thanomsak Sanon; Jettanong Klaewsongkram
Journal:  Exp Ther Med       Date:  2015-06-05       Impact factor: 2.447

7.  Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients.

Authors:  Yan Zhang; Jin Wang; Li-Mei Zhao; Wei Peng; Guo-Qing Shen; Ling Xue; Xiao-Xian Zheng; Xiao-Jing He; Chun-Yan Gong; Li-Yan Miao
Journal:  Eur J Clin Pharmacol       Date:  2011-03-19       Impact factor: 2.953

8.  An exploratory factor analysis of the spontaneous reporting of severe cutaneous adverse reactions.

Authors:  Manfred Hauben; Eric Hung; Wen-Yaw Hsieh
Journal:  Ther Adv Drug Saf       Date:  2016-11-29

Review 9.  Cutaneous drug reactions in children: an update.

Authors:  Kara Heelan; Neil H Shear
Journal:  Paediatr Drugs       Date:  2013-12       Impact factor: 3.022

10.  Purulent bullous epidermal necrolysis: A potential new clinical pattern of drug eruption.

Authors:  Lun-Fei Liu; Jian-Liang Yan; Jian-You Wang; Ji-Su Chen; Sui-Qing Cai; Li-Min Lao; Min Zheng
Journal:  Exp Ther Med       Date:  2013-02-01       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.